FIRST-IN-MAN CLINICAL TRIAL OF INTRAPUTAMENAL CDNF IN PARKINSON’S DISEASE FINDS A CONSORTED BIOMARKER RESPONSE IN A SUBGROUP OF SUBJECTS
Objective: In the first-in-man clinical study of intermittent intraputamenal monthly infusions of CDNF in subjects with moderately advanced PD, we explored cerebrospinal fluid (CSF) biomarkers…Exploring the Potential Anti-dementia Roles of Selected Herbal Anti-inflammatory Remedies in Parkinson’s Disease: Hopes and Challenges
Objective: To evaluate anti-dementia properties of the selected herbal anti-inflammatory remedies Background: Parkinson’s disease (PD) is the most common age-related neurodegenerative disease after Alzheimer’s disease.…Safety and Tolerability of a Ketone Supplement in Parkinson’s Disease
Objective: To investigate the safety and tolerability of a high-dose exogenous ketone supplement in people with Parkinson’s Disease (PD). Background: Animal models and small pilot…STATINS IN PARKINSON’S DISEASE: INFLUENCE ON MOTOR PROGRESSION
Objective: To evaluate whether long-term statin use may affect motor progression in a large cohort of de novo patients with Parkinson's Disease. Background: Statins are…Pilot study of Phenotype of Antisense-Oligonucleotide-(ASO)-knockdown of Cerebral-Dopamine-Neurotrophic-Factor (CDNF) as Parkinson Disease model : implications for PD and related Dementia Therapeutics
Objective: Our objective is twofold: 1)to examine whether CDNF-ASO paradigm can induce a unique phenotype mimicking PD/PDD/LBW in the rodent species; 2) to evaluate whether…CHAPERONIC PROPENSITIES OF AFRICAN WALNUT AS A THERAPEUTIC TARGET IN MANGANESE-INDUCED PARKINSON-LIKE NEUROPATHOLOGY IN WISTAR RATS
Objective: Herein, the chaperonic propensities of ethanolic extract of African walnut (WNE) in Manganese-induced Parkinson-like neuropathology in the prefrontal cortex and hippocampus was investigated. Background:…Inhibition of GluN2D-containing NMDA receptors alleviates the loss of dopaminergic neurons and behavioral deficits in 6-OHDA-induced model of Parkinson’s disease
Objective: The aim of this study is to explore whether the inhibition of GluN2D-containing NMDA receptors (NMDAR2D) can delay the pathological manifestations of Parkinson's disease…Reduced Striatal VMAT2 in REM Sleep Behavior Disorder: A Gateway to Preclinical Parkinson’s Disease
Objective: To determine the degree of striatal degeneration that occurs in subjects with REM Sleep Behavior Disorder (RBD) and assess whether this is an appropriate…Phase I-II first-in-human clinical trial of intraputamenal CDNF in Parkinson’s disease: Topline results of the six-month double-blind placebo-controlled main study and the six-month active treatment extension study
Objective: To assess the safety and tolerability and to explore the preliminary efficacy of intermittent intraputamenal monthly infusions of CDNF in subjects with advanced idiopathic…Phase I-II first-in-human clinical trial of intraputamenal CDNF in Parkinson’s disease: Exploratory fluid-based biomarker endpoints of the 12-month treatment period
Objective: To explore fluid-based biomarkers in subjects with advanced idiopathic Parkinson’s disease (PD) before and after intermittent intraputamenal monthly infusions of CDNF. Background: CDNF is…
- « Previous Page
- 1
- …
- 4
- 5
- 6
- 7
- 8
- …
- 15
- Next Page »